Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Ajouter les origines des ingrdients pour ce produit Signaler un problme Informations incompltes ou incorrectes
Retatrutide is an investigational triple agonist peptide currently under clinical development, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
At the technology transfer level, the development of targeted delivery platforms leveraging biomimetic materials or synthetic biology must prioritize two fundamental challenges: improving bacterial colonization stability within the complex intestinal microenvironment and resolving functional heterogeneity across strains
N., S., & Gholamalizadeh, M
US$ 22.93
US$ 24.81
US$ 27.54
US$ 20.72
